EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA ...

In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

“We are pleased to have recently completed enrollment in our Phase 2b trial evaluating VYN201 for the treatment of vitiligo, which marks an important milestone for the program and reflects the ...

A few days ago, millions around the world cheered when the US Food and Drug Administration (FDA) approved a treatment for vitiligo - a topical cream that can restore pigment with unprecedented ...

Healio compiled the most-read vitiligo articles of 2024. Image: Adobe Stock. Other top stories include Healio’s Beneath the Surface video series, clinical data on novel treatment options and ...

US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo.